At a recent meeting, Jessica Faraci, MD, FAAFP, outlined strategies for evaluating routine cardiovascular concerns during ...

Hormone replacement therapy use may be associated with higher mean incidence, frequency, and duration of migraine among postmenopausal women.

Concomitant hormone therapy is associated with greater weight loss with use of semaglutide among midlife women treated for overweight or obesity.

A tailored health coach intervention significantly reduces low-density lipoprotein cholesterol levels in veterans with cardiovascular disease.

Patients with advanced cardiometabolic disease face a higher risk for major adverse cardiac events after metabolic bariatric surgery.

GLP-1 receptor agonists are linked to lower rates of all-cause mortality and ischemic stroke in adults with obesity and elevated C-reactive protein.

Researchers evaluated the impact of menopausal hormone therapy on cardiovascular disease risk among women in midlife experiencing vasomotor symptoms.

A new generic hormone therapy patch used to treat symptoms of menopause will be available following recent FDA approval.